Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization:: a technical review with interpretive guidelines

被引:124
作者
Hicks, DG
Tubbs, RR
机构
[1] Cleveland Clin Fdn, Lerner Coll Med, Dept Clin Pathol, Cleveland, OH 44195 USA
[2] Cleveland Clin Fdn, Dept Anat Pathol, Cleveland, OH 44195 USA
关键词
HER2; FISH; immunohistochemistry;
D O I
10.1016/j.humpath.2004.11.010
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Diagnostic assays for HER2 in breast cancer provide important prognostic information and independently help guide management by identifying patients who are the most likely to benefit from Herceptin-targeted therapy. The biological events underlying HER2-driven breast cancer that can be assessed in routine clinical specimens include the evaluation of gene amplification by fluorescence in situ hybridization (FISH), enhanced messenger RNA expression by real-time polymerase chain reaction, and the assessment of protein overexpression at the tumor cell membrane by immunohistochemistry (IHC). Immunohistochemistry and FISH methodologies have the advantage of being morphologically driven, allowing for correlations between HER2 expression and morphologic features. However, each has important advantages and disadvantages, which are discussed in detail. Although immunohistochemistry is familiar and readily accommodated in most Surgical pathology laboratories, increasing demands for FISH testing in the clinical setting will require greater familiarity with the technical aspects of FISH assays and their interpretation by the greater laboratory community. In this review, we provide an overview of FISH testing for HER2 in breast cancer, with an emphasis on technical considerations, interpretive guidelines, scoring criteria, and quality control. The development of automated platforms for hybridization, image analysis for signal enumeration, and experience with FISH interpretation Should broaden the availability of this technology for clinical diagnostic testing. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:250 / 261
页数:12
相关论文
共 54 条
[1]  
[Anonymous], 2001, Proc Am Soc Oncol
[2]   The clinical evaluation of HER-2 status: which test to use? [J].
Bartlett, J ;
Mallon, E ;
Cooke, T .
JOURNAL OF PATHOLOGY, 2003, 199 (04) :411-417
[3]  
Bartlett JMS, 2004, METH MOLEC MED, V97, P89
[4]  
Bartlett JMS, 2004, METH MOLEC MED, V97, P77
[5]   Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder? [J].
Bartlett, JMS ;
Watters, AD ;
Ballantyne, SA ;
Going, JJ ;
Grigor, KM ;
Cooke, TG .
BRITISH JOURNAL OF CANCER, 1998, 77 (12) :2193-2198
[6]  
Bartlett JMS, 1999, BJU INT, V84, P775
[7]   Evaluating HER2 amplification and overexpression in breast cancer [J].
Bartlett, JMS ;
Going, JJ ;
Mallon, EA ;
Watters, AD ;
Reeves, JR ;
Stanton, P ;
Richmond, J ;
Donald, B ;
Ferrier, R ;
Cooke, TG .
JOURNAL OF PATHOLOGY, 2001, 195 (04) :422-428
[8]   2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology [J].
Bast, RC ;
Ravdin, P ;
Hayes, DF ;
Bates, S ;
Fritsche, H ;
Jessup, JM ;
Kemeny, N ;
Locker, GY ;
Mennel, RG ;
Somerfield, MR .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1865-1878
[9]   Current perspectives on HER2 testing:: A review of national testing guidelines [J].
Bilous, M ;
Dowsett, M ;
Hanna, W ;
Isola, J ;
Lebeau, A ;
Moreno, A ;
Penault-Llorca, F ;
Rüschoff, J ;
Tomasic, G ;
de Vijver, MV .
MODERN PATHOLOGY, 2003, 16 (02) :173-182
[10]   TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas [J].
Bofin, AM ;
Ytterhus, B ;
Hagmar, BM .
CYTOPATHOLOGY, 2003, 14 (06) :314-319